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The cost-effectiveness of noninvasive tests (NITs) as alternatives to liver biopsy is
unknown. We compared the cost-effectiveness of using NITs to inform treatment deci-
sions in adult patients with chronic hepatitis C (CHC). We conducted a systematic
review and meta-analysis to calculate the diagnostic accuracy of various NITs using a
bivariate random-effects model. We constructed a probabilistic decision analytical model
to estimate health care costs and outcomes (quality-adjusted life-years; QALYs) using
data from the meta-analysis, literature, and national UK data. We compared the cost-
effectiveness of four treatment strategies: testing with NITs and treating patients with
fibrosis stage F2; testing with liver biopsy and treating patients with F2; treat none;
and treat all irrespective of fibrosis. We compared all NITs and tested the cost-
effectiveness using current triple therapy with boceprevir or telaprevir, but also modeled
new, more-potent antivirals. Treating all patients without any previous NIT was the
most effective strategy and had an incremental cost-effectiveness ratio (ICER) of £9,204
per additional QALY gained. The exploratory analysis of currently licensed sofosbuvir
treatment regimens found that treat all was cost-effective, compared to using an NIT to
decide on treatment, with an ICER of £16,028 per QALY gained. The exploratory anal-
ysis to assess the possible effect on results of new treatments, found that if SVR rates
increased to >90% for genotypes 1-4, the incremental treatment cost threshold for the
“treat all” strategy to remain the most cost-effective strategy would be £37,500. Above
this threshold, the most cost-effective option would be noninvasive testing with mag-
netic resonance elastography (ICER5 £9,189). Conclusions: Treating all adult patients
with CHC, irrespective of fibrosis stage, is the most cost-effective strategy with currently
available drugs in developed countries. (HEPATOLOGY 2014;60:832-843)
C
hronic hepatitis C (CHC) virus infection is
one of the main causes of chronic liver disease,
with an estimated 130-170 million persons
infected worldwide. The natural history of the disease
is variable, and it is estimated that one third of
infected patients will progress to cirrhosis in less than
20 years, whereas another one third will never progress
to cirrhosis.1 Antiviral treatment can eradicate the virus
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and stop further fibrosis progression. With current
antiviral treatment, sustained virological response
(SVR) rates are 75% for genotype 1 and 80% for
genotypes 2 and 3.2 These rates are going to further
increase in the next 5 years, because more-effective
antivirals are being developed.
There has always been a dilemma concerning which
patients to treat, because interferon (IFN)-based treat-
ments have considerable side effects and not all
patients with CHC will progress to cirrhosis. Indeed,
antiviral treatment has been advocated for patients
with fibrosis stage F2, whereas those with less fibrosis
could potentially wait.3 A caveat to this strategy was
the need for liver biopsy in order to assess the extent
of fibrosis. Therefore, clinical practice evolved to treat
most patients with antiviral treatment without a liver
biopsy, irrespective of fibrosis stage.
The recent explosive development and use of noninva-
sive tests (NITs) for evaluating fibrosis has led to ques-
tioning this approach, particularly because more effective
treatments with fewer side effects will soon become avail-
able and thus patients can potentially wait. Moreover,
because NITs can be performed serially in the same
patient and therefore the evolution of fibrosis can be
monitored, this newer paradigm is used more often.
Therefore, the use of NITs before deciding to start anti-
viral therapy might be a more cost-effective approach
given the increased costs of new therapies.4 In the cur-
rent study, we assessed the cost-effectiveness of such tests
for treatment decisions in adult patients with CHC.
Materials and Methods
Systematic Review. We performed a systematic
review and meta-analysis to determine the diagnostic
accuracy of NITs, compared to liver biopsy, in adult
patients with CHC. This was part of a larger project
funded by the UK National Institute for Health
Research Health Technology Assessment Program that
determined the cost-effectiveness of NITs in patients
with hepatitis B virus, hepatitis C virus (HCV), alco-
holic liver disease, and nonalcoholic fatty liver disease.
The study is registered in the PROSPERO database
(PROSPERO 2011:CRD42011001561).
Study Selection and Data Extraction. MED-
LINE, Embase, and Science Citation Index Expanded
were searched from 1988 until April 2012 for all avail-
able studies of NITs across all etiologies of liver disease
as part of the larger project. Studies that reported on
patients with HCV were selected and included for this
article. Reference lists of identified studies and reviews
and conference proceedings from recent hepatology
conferences (last 2 years) were hand searched to iden-
tify further studies. The search strategy is provided in
the Web Appendix (see the Supporting Information).
We included full articles and abstracts, which provided
the data necessary to determine the number of true posi-
tive (TP), true negative (TN), false positive (FP), and
false negative (FN) results of the NITs forF2 using liver
biopsy as the reference standard, irrespective of language
or publication status. We excluded studies that reported
on fewer than 10 patients and when the maximum inter-
val between liver biopsy and the NITs was >6 months.
Study selection and data extraction were performed
independently by two researchers. Data were entered
into a specifically created Excel file. The quality of the
included studies was assessed independently by two
researchers using the QUADAS-2 tool.5 The criteria
used for QUADAS-2 assessment are shown in the
Web Appendix (see the Supporting Information).
Data Analysis. The data were combined using the
bivariate random-effects model,6 with correlation
between sensitivity and specificity using the META-
DAS macro developed by the SRDTA Working Group
in the SAS 9.2 statistical software (SAS Institute Inc.,
Cary, NC).7 For tests with explicit thresholds, such as
serum markers, we calculated the summary sensitivity
and specificity at specific thresholds. If the results did
not converge using the above-mentioned random-
effects model with a correlation between sensitivity
and specificity, we performed the meta-analysis with
variations of bivariate analysis, which included bivari-
ate random-effects model without correlation, fixed-
effect model for sensitivity and random-effects model
for specificity, random-effects model for sensitivity and
fixed-effect model for specificity, and fixed-effects
model for both sensitivity and specificity, depending
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upon the distribution of sensitivities and specificities
across the studies. We also calculated the median, low-
est, and highest prevalence for the specific stages of
fibrosis in the included studies.
Economic Evaluation: Approach to Analysis. The
systematic review identified 57 relevant NITs for use
in CHC. We assessed the cost-effectiveness of the
NITs in the context of treating patients with fibrosis
stage F2. Additional comparators for the strategies
including NITs were: (1) treat all patients with CHC
irrespective of fibrosis; (2) treat none; and (3) biopsy
all and treat those with fibrosis stage F2.
We initially conducted an analysis where we com-
pared single NITs to each other. We assumed that only
patients who tested positive (TP or FP) would receive
immediate treatment with anti-viral agents. We then
conducted a second analysis, which evaluated the use
of more than one test, combined based on four
sequential test strategies which are or could potentially
be used in clinical practice (see Table 1). Given the
large number of tests, it was not feasible to model
combinations of all identified NITs; therefore, we
chose six NITs from within three defined test catego-
ries (indirect serum markers, direct and patented
serum markers, and imaging modalities). To choose
the six NITs, we used a decision rule whereby we
chose the best NIT (defined as the most cost-effective
NIT at a cost-effectiveness threshold of £20,000) from
within each category with a defined diagnostic cutoff
(high or low) and the best NIT without any defined
cut-off. We assumed that NITs used sequentially were
independent of each other.
The second analysis compared the six chosen NITs
used singly, combinations of the six NITs based on the
four sequential testing strategies (Table 1), liver biopsy,
“treat all” and “treat no one,” four published algo-
rithms for CHC (SAFE, Fibropaca, Bordeaux, and
Leroy), which are a combination of NITs used sequen-
tially or concomitantly, and several NITs with a dual
diagnostic threshold (a high cutoff with high specificity
and a low cutoff with high sensitivity; when these cut-
offs are combined to minimize the number of FPs and
FNs, then a number of patients falling between the
two cutoffs have indeterminate results and need further
testing), resulting in a comparison of 56 strategies in
the second analysis.
Model Structure. The analyses were based on a
decision tree, combined with a Markov model to esti-
mate the long-term costs and outcomes associated with
each potential NIT diagnosis: TP, FP, FN, or TN and
the treat all and treat no one testing strategies. The
Markov model estimated the lifetime mean costs and
outcomes for a hypothetical cohort of 1,000 patients
with CHC genotypes 1-4, with suspected fibrosis, who
would usually present for liver biopsy. The model
structure is a modified version of previously published
models of liver fibrosis in CHC (Fig. 1).8,9 We vali-
dated the model natural history outputs using data
from a study that retrospectively assessed a cohort of
patients who did not attain SVR after IFN treat-
ment10; the outputs were similar for patients with F4.
Health outcomes were expressed as quality-adjusted
life-years (QALYs), which combine data on life expect-
ancy with data reflecting quality of life (sometimes
referred to as “utility” data). The study was carried out
from a UK National Health Service perspective. A thresh-
old value for incremental cost-effectiveness was assumed
to be £20,000 per additional QALY gained, based on the
lower boundary of UK guidelines, and was varied in sen-
sitivity analysis.11 A discount rate of 3.5% was applied to
costs and QALYs.11 The decision tree was populated with
results from the Markov model, summary sensitivity and
specificity, and average disease prevalence to estimate the
cost-effectiveness of all comparators.
Input Parameters. The disease prevalence for the
F0-F1, F2-F3, and F4 health states as well as the diag-
nostic accuracy of the NITs were estimated using data
from the systematic literature review.
In accord with UK national guidelines, treatment
reflected in the model was a combination of pegylated
IFN (Peg-IFN)-a-2a or -a-2b, ribavirin (RBV), and
telaprevir (TVR) or boceprevir (BOC), depending
upon the genotype.12-15 Genotype 1 patients received
triple therapy (TT) with BOC or TVR (50/50 split).
Table 1. Sequential Testing Approach: Hepatitis C Model
First NIT Result Second NIT Result
Positive Negative Positive Negative
Strategy 1 Treat patients Liver biopsy
Strategy 2 Do second test Watchful waiting Treat patients Liver biopsy
Strategy 3 Do second test Liver biopsy Treat patients Liver biopsy
Perform two NITs regardless of test outcome
Strategy 4 Agree (1): treat Agree: treat or watchful waiting
Agree (2): watchful waiting Disagree: liver biopsy
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Treatment was initiated if the diagnostic test result
(from the NITs used singly or in combination) was
equal to a Metavir score of moderate fibrosis (F2;
TP and FP). Otherwise, a strategy of “watchful
waiting” was initiated whereby patients would be
retested with a NIT every 2 years. The effect of treat-
ment in the model was based on SVR rates, such that
if patients achieved SVR, they no longer retained the
risk of progression to a worse disease stage and
reverted to general population mortality rates.
The rate of disease progression in the Markov
model was sourced from a published cost-effectiveness
study by Wright et al.9; early disease stage costs (F4)
and health-related utility data were also sourced from
this study; as per National Institute for Health and
Clinical Excellence (NICE) guidance,11 the data were
based on patients’ self-reported health status using the
EQ-5D questionnaire in a UK population.16 Later dis-
ease stage costs and utilities were estimated using the
raw data from a cost-effectiveness study of liver trans-
plantation (LT).17 We incorporated adverse effects
(AEs) associated with Peg-IFN-a treatment in the
model by applying a disutility during treatment, using
data from Wright et al.9 We allowed for an increased
EQ-5D value post–successful response (SVR) to
treatment.9
Cohort characteristics, mortality data, SVR rates
after treatment, and treatment costs were sourced from
published literature and routine national UK source of
cost data. All input parameters and sources are listed
in Table 2. Costs for the NITs and liver biopsy are
listed in the Web Appendix (see the Supporting
Information).
Analysis of Results and Uncertainty. We con-
ducted an incremental analysis to identify the cost-
effective testing strategy.18 We ruled out test strategies,
which were more costly and less effective
(“dominated”). We then estimated incremental cost-
effectiveness ratios (ICERs), for the remaining NITs,
where they were compared to the next-best alternative,
calculated using the formula:
ICER ¼ C12C0ð Þ= E12E0ð Þð Þ
where C15 lifetime cost of strategy 1, C05 lifetime cost
of (the next-best) strategy, E15QALYs from strategy 1
and, and E05QALYs from (the next-best) strategy.
Test strategies with an ICER greater than that of a
more-effective intervention (extendedly dominated)
were also ruled out, and the remaining tests were then
compared to identify the NIT leading to the highest
QALY gain given a £20,000/QALY cost-effectiveness
threshold.
Probabilistic sensitivity analysis (PSA) was used to
represent uncertainty in the model, and cost-
effectiveness acceptability frontiers (CEAFs) were
Fig. 1. Illustration of the Markov model used for economic analysis. The disease stages reflect the Metavir staging score for liver fibrosis and
cirrhosis. The cohort represents those suspected of liver fibrosis who can enter the models in one of three disease stages: mild fibrosis (Metavir
stages F0-F1), moderate fibrosis (Metavir stages F2-F3), and compensated cirrhosis (Metavir stage F4), with the proportions determined by the
prevalence estimated from the results of the systematic review (prevalence F2: 53%). Within the model, patients can remain within any disease
stage for longer than one cycle (length of cycle is set as 1 year), except for the LT disease stage, where patients can only progress to either a
post-LT stage or death.
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Table 2. Input Parameters: Hepatitis C Model
Model Inputs Parameters Value PSA distribution (if applicable) Source
Cohort characteristics
Age 40 Wright et al.27
Average weight 79.8 kg Fried et al.28
% male 61 Wright et al.27
Genotype, %
1 66
2 and 3 31 Fried et al.28
4 3
Natural history data
Mild-moderate fibrosis 0.025 Dirichlet Wright et al.27
Moderate fibrosis-compensated cirrhosis 0.037
Cirrhosis-decompensated cirrhosis 0.04
Cirrhosis-HCC 0.14
Decompensated cirrhosis/HCC-LT 0.02
Decompensated cirrhosis-death 0.13
HCC-death 0.43
LT-Death 0.15
Post-LT-death 0.03
All-cause mortality Range from 0.014 to 0.335 Interim life table England
and Wales, 2008-2010
SVR Rate
Treatment Dosage (mg)
Duration
(weeks)
SVR
Rate (%) Source
Genotype 1: treatment na€ıve Peg-IFN-a-2a 180 (weekly) 48 NICE HTA 25213
RBV 1,200 (daily) 48 75
TVR 2,250 (daily 12
Genotype 1: treatment na€ıve Peg-IFN-a-2b 120 (weekly) 48 NICE HTA 25312
RBV 1,000 (daily) 48 66.1
BOC 2,400 (daily) 32
Genotype 1: patients with
cirrhosis (treatment na€ıve)
Peg-IFN-a-2b 120 (weekly) 48 NICE HTA 25312
RBV 1,000 (daily) 48 41.7
BOC 2,400 (daily) 36
Genotypes 2 and 3 (treatment na€ıve) Peg-IFN-a-2a 180 (weekly) 24 76 Fried et al.28
RBV 1,200 (daily) 24
Peg-IFN-a-2b 120 (weekly) 24 82 Manns et al.29
RBV 1,000 (daily) 24
Genotype 4 (treatment na€ıve) Peg-IFN-a-2a 180 (weekly) 48 77 Fried et al.28
RBV 1,200 (daily) 48
Peg-IFN-a-2b 120 (weekly) 48 69 Kamal et al.30
RBV 1,000 (daily) 48
Health State Costs
Mean Standard Error PSA Distribution Source
Mild fibrosis 185 36.39 Wright et al.27
Moderate fibrosis 959 101.69 Gamma
Compensated cirrhosis 1,521 309.05
Decompensated cirrhosis 38,871 9410.46 Longworth et al.17
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constructed. The CEAF plots the uncertainty associ-
ated with the optimal testing strategy, for different val-
ues of the cost-effectiveness threshold (threshold value
range varied from £0 to £60,000).19
Sensitivity Analysis. A number of one-way sensi-
tivity analyses were conducted in order to test the
robustness of our findings.
1. We assumed that there was no increase in utility val-
ues after a successful response (represented by SVR
in the model) to treatment with antiviral agents.
2. We assumed that there was no reduction in utility
values during treatment with antiviral agents.
3. We assumed an additional disutility decrement
value of 0.05 to represent potential AEs from the
use of TVR or BOC in HCV genotype 1 patients.
4. We used higher utility values for all health states.
These values were sourced from a published
Health Technology Assessment (HTA) report.20
5. We changed the prevalence of F2 disease (53%) to
the minimum and maximum estimates extracted
from the meta-analysis (17% and 83%, respectively).
6. The base-case model assumes that patients with
no or mild fibrosis who are treated incorrectly
(test diagnosis of FP) benefit from antiviral treat-
ment. We tested this assumption by reducing the
successful response to treatment (SVR rate) for
this group of patients by decrements of 10%.
7. We conducted an analysis allowing for patients in a
cirrhotic health state who had a successful response
to treatment (SVR) to retain a small risk of progres-
sion to decompensated cirrhosis (0.4%) and hepa-
tocellular carcinoma (HCC; 0.2%) health states.
8. Our base-case analysis assumes that the retest
(from the meta-analysis of the systematic review
data in the watchful waiting strategy for patients
with a negative test result) correctly identified all
patients who had progressed to a health state
Table 2. Continued
Health State Costs
Mean Standard Error PSA Distribution Source
HCC 38,871 9410.46
LT 69,174 7054.86
Post-LT 4,356 861.57
Treatment Costs
Treatment Cost Source
Genotype 1: treatment na€ıve Peg-IFN-a-2a and RBV/TVR 32,809 British National Formulary 64
http://www.bnf.org/bnf/index.htmGenotype 1: treatment na€ıve Peg-IFN-a-2b and RBV/BOC 33,270
Genotype 1: patients with cirrhosis Peg-IFN-a-2b and RBV/BOC 41,670
Genotypes 2 and 3 Peg-IFN-a-2a and RBV 4,446
Genotypes 2 and 3 Peg-IFN-a-2b and RBV 5,435
Genotype 4 Peg-IFN-a-2a and RBV 10,411
Genotype 4 Peg-IFN-a-2b and RBV 10,870
Utilities
Mean Standard Error PSA Distribution Source
Without treatment with antiviral agents
Mild fibrosis 0.77 0.035 Beta Wright et al.27
Moderate fibrosis 0.66 0.018
Compensated cirrhosis 0.55 0.032
Decompensated cirrhosis 0.49 0.056 Longworth et al.17
HCC 0.49 0.056
LT 0.51 0.053
Post-LT 0.52 0.061
Death 0 0
During treatment with antiviral agents
Mild fibrosis (during treatment) 0.65 0.035 Beta Wright et al.27
Moderate fibrosis (during treatment) 0.55 0.018
Compensated cirrhosis (during treatment) 0.44 0.04 Grishchenko et al.31
After successful response to treatment with antiviral agents
Mild fibrosis (SVR after treatment) 0.82 0.04 Beta Wright et al.27
Moderate fibrosis (SVR after treatment) 0.71 0.05
Compensated cirrhosis (SVR after treatment) 0.60 0.04 Grishchenko et al.31
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F2. We tested this assumption by applying the
sensitivity and specificity of three commonly used
tests (aspartate transaminase to platelets ratio
index [APRI], FibroTest, and FibroScan).
9. We assumed a later starting age (50 years) in the
model by amending the rates of all-cause mortal-
ity to reflect a cohort of 50 years. We also
increased the probability of disease progression in
the mild and moderate health states to reflect
those of an older cohort of patients (transition
probability of 0.067 and 0.077 to reflect progres-
sion from a mild to moderate health state from a
moderate to cirrhotic health state, respectively).
10. We incorporated a discontinuation rate for TTwith
BOC or TVR, which had an effect on the total cost
of treatment. The discontinuation rates for BOC
were 4% at week 12 and 2% at week 24 and for
TVR 5% at week 4 and 2% at week 12.13,14
Secondary Analysis. Summary sensitivity and speci-
ficity estimates for some of the NITs were based on
only one study. Taking this into consideration, we con-
ducted a secondary analysis where we evaluated only
those NITs (14 NITs) where the bivariate model for the
meta-analysis converged (used as an indicator of the
magnitude of the evidence base underlying an NIT).
Exploratory Analysis. We conducted an explora-
tory analysis to assess the potential effect of new thera-
pies on the findings for NITs. We assessed the effect
of increased treatment costs and effectiveness to reflect
the use of sofosbuvir (SOF) as part of TT in combina-
tion with Peg-IFN-a-2a/2b and RBV. We assumed
that genotype 1 and 4 patients would receive treatment
with Peg-IFN-a-2a, RBV, and SOF for a total of 12
weeks (SVR rate: 89% and 96%, respectively, with a
total treatment cost of £36,476). We assumed that
genotype 2 patients would receive treatment with RBV
and SOF for a total of 12 weeks (SVR rate without
cirrhosis: 92%; SVR rate with cirrhosis: 94%; with a
total treatment cost of £35,723). We assumed that
genotype 3 patients would receive treatment with RBV
and SOF for a total of 24 weeks (SVR rate without
cirrhosis: 94%; SVR rate with cirrhosis: 92%; with a
total treatment cost of £71,466).21
We further assessed potential new IFN-free therapies
with assuming an SVR rate of 90% for genotype 1,
92% for genotypes 2 and 3, and 94% for genotype 4.
Results
Meta-Analysis. The selection flow chart for studies
is shown in Fig. 1 (Web Appendix in the Supporting
Information). Data on patients with HCV were
extracted from 162 studies (Web Appendix in the Sup-
porting Information). NIT cutoffs for the diagnosis of
specific histological stages were not always predeter-
mined and, consequently, varied. Cutoffs were grouped
into narrow ranges, as appropriate. Therefore, when a
range of cutoffs is mentioned in the results tables
(Table 3), the reported sensitivities and specificities are
probably overestimated.
A number of mainly indirect NITs reported sensitiv-
ities and specificities at dual cutoffs, one high and one
low. The low and high cut-off threshold is usually set
at 90%-95% of sensitivity and specificity, respectively.
We performed separate meta-analyses of low and high
cutoffs whenever such cutoffs were reported.
The most commonly evaluated NITs for F2 were
APRI (low cutoff ), which was evaluated in 47 studies,
followed by FibroScan in 37 studies and APRI (high
cutoff ) in 36 studies. Summary sensitivity and specific-
ity of NITs for diagnosis of F2 is shown in Table 3.
Overall, only five studies had low risk of bias in all the
domains of the QUADAS-2 tool; therefore, all our
estimates may be biased. A table of the quality assess-
ment of included studies based on QUADAS-2 is in
the Web Appendix (see the Supporting Information).
Economic Modeling. The most cost-effective strat-
egy is to adopt a treat all approach with an ICER of
£9,204. This ICER reflects that the treat all strategy
has a QALY gain of 0.47 at an additional cost of
£4,287, compared to the next-best alternative (Fibro-
Spect and FibroScan) and is within the standard UK
threshold range for cost-effectiveness. Table 4 displays
results of the base-case analysis (second stage of the
analyses); for clarity of presentation, only test strategies
that were not “dominated” or “extendedly dominated”
are shown in the table (see the Web Appendix in the
Supporting Information for full table and results of
the comparison of NITs evaluated as single tests). The
CEAF (Fig. 2) shows that the probability of treat all
being cost-effective, given a cost-effectiveness threshold
value of £20,000, is 45%.
Sensitivity Analyses. The base-case analysis result
remained robust to the majority of the sensitivity anal-
yses. Analyses that changed the base-case result are
detailed below.
Amending the assumption that patients who were
treated incorrectly (patients with mild fibrosis [F0-F1]
who test FP), benefitted from treatment, changed the
base-case results. We reduced the SVR rate (representa-
tive of treatment benefit) for these patients by decre-
ments of 10%. When the SVR rate was reduced by
more than 23%, treat all was no longer cost-effective.
The illustrative graph (see Fig. 2 in the Web Appendix
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Table 3. Diagnostic Accuracy of NITs for Detection of Fibrosis Stage F2 in Patients With CHC
Test
Number of
Studies Cutoff
Summary
Sensitivity 95% CI
Summary
Specificity 95% CI Statistics
Indirect noninvasive serum tests
APRI (low cutoff) 47 0.4-0.7 0.82 0.77-0.86 0.57 0.49-0.65 Bivariate random-effects model with
correlation between sensitivity and
specificity
APRI (high cutoff) 36 1.5 0.39 0.32-0.47 0.92 0.89-0.95 Bivariate random-effects model with
correlation between sensitivity and
specificity
Age_Platelet index 1 3 0.58 0.46-0.70 0.70 0.64-0.84 Single study
AST_ALT_ratio 7 0.6-1 0.44 0.27-0.63 0.71 0.62-0.78 Bivariate random-effects model with
correlation between sensitivity and
specificity
Cirrhosis discriminant score 1 6 0.66 0.59-0.73 0.49 0.34-0.64 Single study
FIB-4 (low cutoff) 11 0.6-1.45 0.89 0.79-0.95 0.42 0.25-0.61 Random-effects model for sensitivity
and specificity without correlation
FIB-4 (high cutoff) 9 1-3.25 0.59 0.43-0.73 0.74 0.56-0.87 Bivariate random-effects model with
correlation between sensitivity and
specificity
Forns index (low cutoff) 18 4.2-4.5 0.88 0.83-0.91 0.40 0.33-0.48 Bivariate random-effects model with
correlation between sensitivity and
specificity
Forns index (high cutoff) 15 6.9-8.7 0.35 0.29-0.41 0.96 0.92-0.98 Bivariate random-effects model with
correlation between sensitivity and
specificity
FibroQ 1 1.6 0.78 0.71-0.83 0.66 0.51-0.78 Single study
Fibrosis probability index (low
cutoff)
2 0.2 0.91 0.83-0.96 0.45 0.34-0.57 Fixed-effects model for sensitivity and
specificity without correlation
Fibrosis probability index (high
cutoff)
2 0.8 0.42 0.32-0.54 0.95 0.87-0.98 Fixed-effects model for sensitivity and
specificity without correlation
GUCI 3 0.33-1.1 0.65 0.1-1.00 0.79 0.03-1.00 Bivariate random-effects model with
correlation between sensitivity and
specificity
Kings 1 9.87 0.84 0.75-0.9 0.70 0.61-0.79 Single study
Kings (low cutoff) 1 4.46 0.62 0.55-0.69 0.81 0.76-0.86 Single study
Kings (high cutoff) 1 12.3 0.58 0.51-0.65 0.79 0.73-0.83 Single study
Lok’s model 4 0.2-1.67 0.67 0.55-0.77 0.55 0.29-0.78 Bivariate random-effects model with
correlation between sensitivity and
specificity
Platelets 10 48-182 0.50 0.41-0.59 0.89 0.83-0.93 Bivariate random-effects model with
correlation between sensitivity and
specificity
Pohl index 2 Positive 0.06 0.04-0.1 0.99 0.93-1.00 Fixed-effects model for sensitivity and
specificity without correlation
Direct serum noninvasive serum tests
Aminopyrine breath test 1 8.1 0.73 0.57-0.85 0.74 0.58-0.85 Single study
Hyaluronic acid 8 34-110 ng/mL 0.75 0.64-0.83 0.75 0.68-0.82 Bivariate random-effects model with
correlation between sensitivity and
specificity
Hepascore 10 0.31-0.5 0.73 0.66-0.79 0.73 0.65-0.79 Bivariate random-effects model with
correlation between sensitivity and
specificity
Hepascore (high cutoff) 1 0.84 0.33 0.24-0.43 0.92 0.85-0.96 Single study
MP3 1 0.3 0.82 0.73-0.89 0.73 0.63-0.81 Single study
PIIINP 2 8.3-9.1 0.78 0.63-0.87 0.76 0.54-0.90 Fixed-effects model for sensitivity and
specificity without correlation
PIIINP/MMP-1 index 1 0.3 0.65 0.55-0.75 0.85 0.77-0.90 Single study
Type IV collagen 5 110-298 0.88 0.71-0.96 0.73 0.63-0.82 Random-effects model for sensitivity
and specificity without correlation
YKL-40 (low cutoff) 1 290 0.80 0.66-0.89 0.33 0.26-0.41 Single study
YKL-40 (high cutoff) 1 540 0.33 0.21-0.48 0.80 0.73-0.86 Single study
Commercial noninvasive serum tests
ELF 1 8.75 0.84 0.69-0.92 0.70 0.52-0.83 Single study
ELF (low cutoff) 1 9.55 0.90 0.85-093 0.52 0.43-0.61 Single study
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in the Supporting Information) shows the increase in
the ICER for treat all as the assumption around treat-
ment benefit for this group of patients is relaxed.
Secondary Analysis. Using only those 14 NITs
where the bivariate model for the meta-analysis con-
verged did not change the overall result, and treat all
remained cost-effective with an ICER of £8,162.
Exploratory Analyses. The exploratory analysis to
assess the possible effect on results of increased costs
and effectiveness associated with treatment with Peg-
IFN-a-2a, RBV, and SOF found that the base-case
analysis results remained the same and treat all was
still the most cost-effective strategy to adopt, compared
to no treatment or only treating patients F2 with
Peg-IFN-a-2a, RBV, and SOF (genotypes 1 and 4) or
RBV and SOF (genotypes 2 and 3), though with a
higher ICER of £16,028 (full table in the Web Appen-
dix in the Supporting Information).
The exploratory analysis on new treatments found
that if SVR rates were 90% for genotypes 1 and 4 and
Table 3. Continued
Test
Number of
Studies Cutoff
Summary
Sensitivity 95% CI
Summary
Specificity 95% CI Statistics
ELF (high cutoff) 1 11.07 0.47 0.41-0.54 0.90 0.83-0.94 Single study
FibroIndex (low cutoff) 4 1.25 0.83 0.15-0.99 0.57 0.22-0.86 Random-effects model for sensitivity
and specificity without correlation
FibroIndex (high cutoff) 4 2.25 0.24 0.11-0.43 0.98 0.93-1.00 Random-effects model for sensitivity
and fixed-effect model for specificity
without correlation
FibroMeter 4 0.42-0.57 0.79 0.69-0.86 0.73 0.63-0.81 Bivariate random-effects model with
correlation between sensitivity and
specificity
FibroSpect II 5 42-72 0.78 0.49-0.93 0.71 0.59-0.80 Random-effects model for sensitivity
and specificity without correlation
FibroTest 17 0.32-0.53 0.68 0.58-0.77 0.72 0.70-0.77 Bivariate random-effects model with
correlation between sensitivity and
specificity
FibroTest (low cut-off) 7 0.1-0.3 0.91 0.86-0.94 0.41 0.37-0.46 Random-effects model for sensitivity
and specificity without correlation
Fibrotest (high cutoff) 10 0.6-0.7 0.57 0.46-0.67 0.85 0.74-0.92 Bivariate random-effects model with
correlation between sensitivity and
specificity
Imaging modalities
ARFI 3 1.21-1.34 0.79 0.75-0.83 0.89 0.84-0.93 Fixed-effects model for sensitivity and
specificity without correlation
MRE 3 — 0.94 0.13-1 0.92 0.72-0.98 Model 3; random effects for sensitivity
and fixed effect for specificity
PLT_spleen ratio 3 1750-2200 0.88 0.62-0.99 0.73 0.41-0.99 Bivariate random-effects model with
correlation between sensitivity and
specificity
FibroScan 37 5.2-10.1 0.79 0.74-0.84 0.83 0.77-0.88 Bivariate random-effects model with
correlation between sensitivity and
specificity
US 3 — 0.35 0.14-0.63 0.86 0.59-0.96 Metadas
US_SAPI 3 — 0.74 0.69-0.79 0.79 0.72-0.85 Model 5; fixed-effect model for both
US_SAPI (high cutoff) 2 — 0.61 0.54-0.68 0.96 0.9-0.98 Model 5; fixed-effect model for both
US_SAPI_F2 (low cutoff) 2 — 0.94 0.9-0.97 0.39 0.31-0.49 Model 5; fixed-effect model for both
Combination of fibrosis noninvasive tests algorithms
Bordeaux 1 — 0.88 0.85-0.91 0.89 0.85-0.92 Single study
Fibropaca 1 — 0.85 0.81-0.89 0.90 0.86-0.93 Single study
Leroy 1 — 0.90 0.79-0.96 0.98 0.95-0.99 Single study
SAFE 4 — 1.00 1.00-1.00 0.81 0.80-0.83 Fixed-effects model for sensitivity and
specificity without correlation
Bordeaux consists of the synchronous use of FibroTest and FibroScan, followed by liver biopsy in cases of discordance. Fibropaca consists of the synchronous
use of FibroTest plus APRI and/or Forns, followed by liver biopsy in cases of discordance. Leroy consists of the synchronous use of FibroTest plus APRI, followed by
liver biopsy in patients with intermediate values. SAFE is a sequential algorithm that consists of APRI as the initial test followed by FibroTest in the indeterminate
fibrosis cases or liver biopsy in patients with low risk of fibrosis according to APRI.
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; GUCI, G€oteborg University Cirrhosis Index; MP3 score, combination of PIIINP and
MMP-1; PIIINP, N-terminal procollagen III; MMP-1, matrix metalloproteinase 1; YKL-40, human cartilage glycoprotein 39; ELF, enhanced liver fibrosis score; ARFI,
acoustic radiation force impulse; PLT_spleen ratio, platelet to spleen size ratio; US, ultrasound; US_SAPI, ultrasonographic evaluation of the splenic artery pulsatility
index; CI, confidence interval.
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costs increased by £20,000 for all genotypes, the base-
line results do not change substantially, with the treat
all strategy remaining the most cost-effective strategy
with an ICER of £10,009. However, increasing the
additional cost by £40,000 increases the ICER for the
treat all strategy to £21,174, which would not be cost-
effective given a £20,000 threshold. The most cost-
effective option in this case would be testing with
magnetic resonance elastography (MRE) and treating
those patients with F2, with an ICER of £9,189.
The incremental treatment cost threshold for the treat
all strategy to remain the most cost-effective strategy
was determined at £37,500.
Discussion
The results of our economic modeling and analysis
indicate that a treat all strategy with currently available
drugs is the most cost-effective strategy in patients
with CHC in the UK. Given the similar health costs
and treatment pathways for CHC in Western coun-
tries, it is reasonable to extrapolate that this holds true
for most countries in the developed world.
Our meta-analysis of NITs has been the most
detailed and extensive to date, including all described
serum tests and imaging modalities with no language
restrictions and using state-of-the-art statistical and
reporting methods. A recent systematic review only
included serum tests and did not report on summary
sensitivity and specificity, but chose to present median
values.22 A striking finding of our meta-analysis was
that the vast majority of studies (98%) had high risk
of bias and failed in important methodological aspects,
such as the absence of predetermined test cutoffs and
suboptimal quality of liver biopsy as the reference
standard. NITs performed significantly better for the
diagnosis of cirrhosis than for lesser fibrosis stages.
Indirect serum NITs, such as APRI and FIB-4, fail to
classify a significant proportion of patients who fall
into the gray zone of indeterminate values. Proprietary
Table 4. Base-Case Analysis*
Test Strategy Costs (£) QALYs Incremental Cost (£) Incremental QALYs ICER (£)
(S4) type IV collagen and PLT spleen 46,911 14.22 — — —
FibroSpect and FibroScan 46,954 14.27 43 0.05 928
Treat all 51,241 14.73 4,287 0.47 9,204
*Second stage of the analysis: comparison of sequential testing strategies, most cost-effective tests from first stage of the analysis, liver biopsy, published algo-
rithms, NIT with a combined cut-off diagnostic threshold, and the treat all and no treatment comparators.
Abbreviation: PLT, platelet.
Fig. 2. CEAFs showing the probability that treat all is cost-effective, compared to alternatives over a range of values for the maximum accepta-
ble cost-effectiveness threshold value (ceiling ratio k) for HCV. PLT_Spleen, platelet/spleen size ratio.
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serum NITs, with the possible exception of FibroTest,
are insufficiently validated in independent cohorts.
The increasingly used FibroScan does not have vali-
dated cutoffs for specific fibrosis stages.23 Therefore,
NITs need better-quality studies and further validation,
particularly for the diagnosis of moderate fibrosis.
Our economic analysis revealed that treating all
CHC patients without testing for fibrosis stage was the
most cost-effective strategy given a cost-effectiveness
threshold of £20,000. This result was robust to most
of the amendments in the sensitivity analysis. A key
driver in the cost-effectiveness results is that patients
with mild fibrosis (F0-F1) gain benefit from treatment,
albeit at an increased cost. We have performed a
threshold analysis to confirm this assumption. For the
treat all strategy to cease to be cost-effective, the rela-
tive treatment benefit would need to be reduced by
only 23%. In addition to mortality and morbidity
associated with liver disease, the analysis reflects the
risk of death from other causes. This was based on
estimates from the UK general population; however,
we recognize that, in practice, some patients with
CHC may have higher mortality rates. This is likely to
underestimate the ICER for the treat all strategy, rela-
tive to the comparators.
Previously published models by Wright et al.9 and
Liu et al.8 evaluated the cost-effectiveness of alternative
treatments for CHC. The results from both studies
show that treating all patients irrespective of fibrosis
level is cost-effective at UK cost-effectiveness thresh-
olds. The analysis by Wright et al. evaluated early
treatment for patients with CHC (all nongenotype 1
patients grouped together). The study by Liu et al.
evaluated different treatment strategies, which included
the use of an NIT (FibroTest) in genotype 1-3
patients, but did not incorporate its diagnostic accu-
racy. This model also assumed a linear progression
from F0 to the F4 health state and assumed that the
costs for the F0-F4 health states were the same. Our
study adds substantially to both of these studies. We
evaluated more treatments than Wright et al. (IFN-a
and RBV and Peg-IFN in a sensitivity analysis) and
Liu et al. (Peg-IFN-a, RBV, and TVR) and also per-
formed exploratory analyses for more-potent antiviral
treatments. Our model incorporated data on differen-
tial rates of disease progression and costs according to
different health states. Most important, we evaluated
57 NITs for use in patients with genotype 1-4 CHC
and incorporated their diagnostic accuracy and the
consequences of TP, FP, FN, and TN results in the
Markov model. This makes our approach unique and
distinct from previous models.
New antiviral treatments with increased efficacy and
lesser side effects for genotypes 1 and 4 will soon be
licensed.21 However, the cost-effectiveness of such
drugs will depend on their price and robust data on
effectiveness. The exploratory analysis presented here
shows that a strategy of treat all with Peg-IFN-a-2a,
RBV, and SOF would be cost-effective, compared to
no treatment or using the NITs to restrict that treat-
ment combination to patients with F2. Given that
other treatment combinations are available, the cost-
effectiveness of SOF needs to be assessed, relative to
currently standard treatments. The exploratory analysis
on other treatments showed that treat all would be
cost-effective if the overall increase in treatment costs
is up to approximately £37,500, but not above. In the
latter case, a strategy of NIT and treatment of patients
with F2 is the most cost-effective strategy. This is of
particular importance, because the pricing of new anti-
viral therapies is not yet known and relative effective-
ness is not fully established. Although the estimates on
diagnostic accuracy of NITs carry a high risk of bias,
our data indicate that if treatment costs increase
beyond a certain point, then testing with NITs of a
defined sensitivity, specificity, and cost will be the most
cost-effective strategy.
Our economic modeling was performed from the
perspective of an economy of a developed country, and
therefore its findings cannot be extrapolated to the
developing world. This would require a separate analy-
sis with the use of different utilities and costs, such as
the one recently performed in Egypt.24 The emergence
of population screening strategies for HCV infection,
as recently recommended in the United States,25 will
result in further increases in health care costs. If the
detection rates increase significantly, even cost-effective
strategies might not be realistic in certain health care
systems. We assumed that NITs used sequentially were
independent of one another. Although this assumption
did not influence the results, it has not been suffi-
ciently tested. We have based the model on SVR being
a valid surrogate outcome and that there are no long-
term adverse events related to protease inhibitors as in
previous economic models.26 Our conclusions will
change if the above is not true.
In conclusion, we have shown that treating all adult
patients with CHC, irrespective of fibrosis stage, is the
most cost-effective strategy with current standard treat-
ments in developed countries. Licensing of more-
potent and expensive antiviral treatment, such as SOF,
does appear to be cost-effective given the current price;
however, more costly combinations could change these
findings. Further analyses of such treatments are
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required to determine their cost-effectiveness. Because
studies of NITs had a high risk of bias, better-quality
data are urgently needed to validate their reported
diagnostic accuracy.
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